Natera (NTRA) Receives News Impact Rating of 0.07

Media coverage about Natera (NASDAQ:NTRA) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Natera earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.1627553634309 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

NTRA has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. Morgan Stanley reiterated an “overweight” rating and set a $16.00 target price (up previously from $13.00) on shares of Natera in a research note on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 target price on shares of Natera in a research note on Tuesday, November 14th. Robert W. Baird reiterated a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Finally, BidaskClub upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $15.00.

Natera (NASDAQ NTRA) remained flat at $$9.50 during midday trading on Wednesday. 87,300 shares of the company’s stock were exchanged, compared to its average volume of 193,363. The company has a quick ratio of 1.75, a current ratio of 1.85 and a debt-to-equity ratio of 2.43. Natera has a one year low of $7.35 and a one year high of $14.76.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The company had revenue of $56.66 million during the quarter, compared to analyst estimates of $55.31 million. During the same quarter in the prior year, the company earned ($0.50) EPS. The business’s revenue was up 5.1% on a year-over-year basis. equities research analysts forecast that Natera will post -2.15 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2017/12/13/natera-ntra-receives-news-impact-rating-of-0-07.html.

Natera Company Profile

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply